Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells

Purpose: Human papilloma virus (HPV) positive head and neck squamous cell carcinoma (HNSCC) tumors respond significantly better to anticancer treatments. It is assumed to be due to a better response to radiotherapy (RT), and presumably to an increased immunogenicity. However, little is known how the...

Whakaahuatanga katoa

I tiakina i:

Ngā taipitopito rārangi puna kōrero
Ngā kaituhi matua:	Fridolin Grottker, Simon Gehre, Clara M. Reichardt, Azzaya Sengedorj, Tina Jost, Thorsten Rieckmann, Markus Hecht, Antoniu-Oreste Gostian, Benjamin Frey, Rainer Fietkau, Udo S. Gaipl, Michael Rückert
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Elsevier 2023-11-01
Rangatū:	Neoplasia: An International Journal for Oncology Research
Ngā marau:	Radiotherapy Docetaxel Head and neck squamous cell carcinoma HPV status Immune checkpoint molecules HMGB1
Urunga tuihono:	http://www.sciencedirect.com/science/article/pii/S1476558623000684
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Radiotherapy combined with docetaxel alters the immune phenotype of HNSCC cells and results in increased surface expression of CD137 and release of HMGB1 of specifically HPV-positive tumor cells

Ngā tūemi rite